On Invalid Date, Stoke Therapeutics (NASDAQ: STOK) reported Q1 2023 earnings per share (EPS) of -$0.53, up 19.7% year over year. Total Stoke Therapeutics earnings for the quarter were -$22.55 million. In the same quarter last year, Stoke Therapeutics's earnings per share (EPS) was -$0.66.
As of Q2 2023, Stoke Therapeutics's earnings has grown year over year. Stoke Therapeutics's earnings in the past year totalled -$98.96 million.
What is STOK's earnings date?
Stoke Therapeutics's earnings date is Invalid Date. Add STOK to your watchlist to be reminded of STOK's next earnings announcement.
What was STOK's revenue last quarter?
On Invalid Date, Stoke Therapeutics (NASDAQ: STOK) reported Q1 2023 revenue of $5.15 million up 71.73% year over year. In the same quarter last year, Stoke Therapeutics's revenue was $3.00 million.
What was STOK's revenue growth in the past year?
As of Q2 2023, Stoke Therapeutics's revenue has grown 385.2% year over year. This is 315.42 percentage points higher than the US Biotechnology industry revenue growth rate of 69.78%. Stoke Therapeutics's revenue in the past year totalled $14.56 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.